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J.S. Lindholt,1* S. Juul,2 H. Fasting1 and E.W. Henneberg11The Vascular Research Unit, Department of Vascular Surgery, Viborg Hospital, DK-8800 Viborg, and
2Department of Epidemiology, Institute of Public Health, Vennelyst Boulevard 6, University of Aarhus,
DK-8000 Aarhus C, DenmarkBackground. The aim of this study was to estimate the cost effectiveness of screening for abdominal aortic aneurysm (AAA).
Material and methods. All 12,639 men born in the years 1921–1933 (aged 64–73) living in Viborg County, Denmark,
were randomly allocated either to receive an invitation to abdominal ultrasound scanning for AAA or to be controls. Costs
for screening and surveillance were assessed prospectively. Diagnosis Related Group (DRG) costs from 1999 were used
concerning admissions with uncomplicated and complicated operations. Admissions for AAA surgery were retrospectively
classified according to complications in patient records.
Results. Mean follow-up time was 52 months. 76.6% of invited men attended screening, and 191 (4.0%) had an AAA. As
previously reported, the cumulative 5-year AAA-specific mortality in the invited group was significantly reduced by 67%
compared to the control group (PZ0.003). The costs were estimated to beV11.23 per scan. The costs per life-year saved were
V9057 (V5872–20,063) after 5 years, and were expected to decrease to V2708 (V1758–6031) after 10 years and to V1825
(V1185–4063) after 15 years.
Conclusion. Screening of 64–73 years old males in Denmark seems cost effective.Keywords: Abdominal aortic aneurysm; Mass screening; Prevention; Randomised controlled trial.Introduction
The elderly population is increasing in virtually all
Western societies, and about 1–3% of men over the age
of 64 will experience rupture of an abdominal aortic
aneurysm (AAA), an event that carries a 70–95%
mortality. AAAs seldom cause symptoms, but if an
AAA is found before rupt
ure, elective repair carries a much lower mortality of
4–6%, suggesting the benefit of screening.1–5 The cost
effectiveness of ultrasound screening for AAA in older
men is uncertain. Previous cost-effectiveness analyses
have mostly been based on uncertain assumptions.6–9
Consequently, the results of these assessments have
ranged from attractive cost effectiveness1,6,9,10 to the
conclusion that screening was harmful and costly.8
The large-scale randomised multicentre aneurysm
screening study (MASS) estimated the cost of AAAwas presented at the 17th annual meeting in the
iety of Vascular Surgery in Dublin 2003.
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probably is below £30,000 per quality adjusted life year
saved.12 However, the costs were projected to decline to
around £8000 per life year saved after 10 years.11 At
about the same time as the MASS trial, our randomised
screening trial was set up in the County of Viborg,
Denmark. We previously reported its main finding: a
significant 67% reduction of AAA mortality during the
first 52 months after randomisation.13 These findings
are used here to assess the cost effectiveness of
screening for AAA in men. We also investigated the
operative complications following screening. Previous
reports, based upon non-randomised data, suggest
elective operations on screen-detected AAA are associ-
ated with fewer complications and lower operative
mortality compared to non-screen-detected cases.14,15Material and Methods
The methods for this cost effectiveness analysis build
on those of our clinical trial, which is described
elsewhere.13 In brief, from 1994 to 1998, all 12,639Eur J Vasc Endovasc Surg 32, 9–15 (2006)
doi:10.1016/j.ejvs.2006.01.014, available online at http://www.sciencedirect.com onved.
J. S. Lindholt et al.10men aged 64–73 years resident in Viborg County in
Denmark were randomly selected to be invited for
screening (intervention arm) or not (control arm). Of
these, 6306 became controls, while 6333 were invited
to receive an abdominal ultrasonographic scan
performed by a mobile screening team at their district
hospital (Fig. 1).
An AAA was considered to be present if the
infrarenal aortic diameter was 3 cm or greater. Patients
with AAAs of 5 cm or more were referred to a vascular
surgeon for consideration for elective repair. The
remaining small AAAs were offered yearly surveillance
to check for any expansion, and referred for surgical
evaluation if the aneurysm became 5 cm or greater in
diameter. Men who were found to have an initial ectatic
aorta (diameter 2.5–2.9 cm) on the initial scan were
offered rescreening after 3–5 years (Fig. 1).16 Data wereAssessed fo
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Eur J Vasc Endovasc Surg Vol 32, July 2006collected from both arms regarding vital status and
elective or emergency aneurysm repairs (see details
below). In the intervention arm, data were also collected
concerning screening attendance, re-invitations, and
follow-up surveillance of small AAAs.Follow-up of subjects
Subjects were followed from randomisation until
death or 31.12.1999. Deaths were identified in the
Danish Civil Registration System and the causes of
death were obtained from the National Register of
Causes of Death. Death certificates with AAA as the
primary or a contributing cause of death were
identified, and hospital and autopsy records were
obtained. Two vascular surgeons, blind to ther eligibility:
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Cost-effectiveness of Screening for AAA 11randomisation group and to each other’s evaluations,
assessed the available hospital records and autopsy
records. Both surgeons assessed each death to be
certainly, possibly, or not caused by AAA. Cases
where both assessors evaluated the death to be
certainly or possibly caused by AAA were classified
as AAA deaths. No efforts were made to obtain
agreement between the ratings.13Estimation of costs
The costs for screening and surveillance were prospec-
tively recorded during the first year of the trial. The data
obtained were salaries and travel reimbursement (for
doctor and nurse), portable ultrasound scanner, stamps,
envelopes, printing costs of invitations, laptop compu-
ter, and various products such as ultrasonographic gel.17
AAA-operations were prospectively registered nation-
wide in the Danish Register of Vascular Surgery
(‘Karbasen’). To assign costs of hospitalization for
surgery, the existing Diagnosis Related Group (DRG)
costs in 1999 were used (www.sum.dk, August 1999).
The DRG costs are the mean hospital costs for the
treatment of a patient with a specific diagnosis. These
are based on independent cost studies from different
hospitals in Denmark. In this study, the AAA-diagnosis
group was that for patients admitted for major vessel
surgery outside the heart. In 1999, the costs associated
with the DRG differentiated between admissions for
operation with, and without, complications. Conse-
quently, medical records were reviewed in order to
identify complications and assign costs accordingly.
Medical and surgical complications consisted of the
following: acute myocardial infarction, cardiac failure,
severe pulmonary complication demanding treatment,
artificial ventilation for more than 48 h, dialysis,
intensive unit stay for more than 72 h, stroke, arrhyth-
mia, wound complications including rupture, re-oper-
ation for bleeding, ileus, re-operation for thrombosis and
peripheral embolisation requiring surgery. Costs were
not discounted because of the short time period
analysed, and indirect costs were not included. A
previous study found that the costs to the participants
and the indirect costs due to production loss were minor
compared to the health care costs.18 All costs were
originally calculated in Danish crowns (DKr), and
transformed to Euro (V) and British pounds (£) based
upon the exchange rate on the 1st of January 2006.Statistical analyses
The clinical trial estimates were conducted on an
intention to treat basis from the date of randomisation.Using the life table for all Danish males in 1995–1996,
the remaining life expectancy was calculated for two
hypothetical cohorts: men invited to screening and
controls, each containing 6333 67-year-old men. For
controls, the number of remaining life-years was
estimated directly from the life tables. The pro-
portional hazards assumption for Cox regression was
not confirmed, both by a graphical assessment and by
test of the proportional-hazards assumption based on
Schoenfeld residuals (PZ0.03) (STATA 8). Conse-
quently, the follow up was split into two time periods,
each with a separate analysis. During the first 18
months after randomisation the AAA mortality was
quite similar between the two groups. Thereafter,
however, the AAA-mortality in the intervention group
was much lower than in the controls. In the cohort
representing the screening group, the mortality for the
period 1.5–5 years after randomisation was assumed
to be reduced by the AAA-specific mortality difference
found in the study (0.89 per 1000 years; 95% CI: 0.40–
1.37); before and after that period mortality was
assumed to be unaffected by screening. It should be
noted that the observed age-specific mortality among
controls was very close to that of all Danish males
during 1995–1996, but because they were observed for
less than 6 years their data could not be used for
projections beyond that.13 In addition, Kaplan–Meier
estimates of mortality from AAAs in the two groups
were calculated for graphical illustration, and Chi
square tests and t-tests were used to compare
operative- and post-operative characteristics includ-
ing complications between the two randomized
groups. Two tailed p values less than 5% were
considered statistically significant.
SPSS 10.0, and Stata 8.0 were used for the analyses.Ethics
The trial was approved by the local scientific ethics
committee and reported to the data protection
authorities. All authors had no competing interest in
the trial and were independent of the funding agency.Results
In total, 12,639 men were included in the trial; the
mean age was 67.7 years (range 64.3–73.8 years)
(Fig. 1). Subjects were followed for 51.9 months on
average, ranging from 0.1 to 69.0 months. No
differences in length of follow-up and age at inclusion
were observed between the invited group and the
control group (data not shown). As previouslyEur J Vasc Endovasc Surg Vol 32, July 2006
Table 1. Pre-, per- and post-operative characteristics of operations for abdominal aortic aneurysms
Screening group Control group
Planned Emergency Total Planned Emergency Total
Numbers (N (% of total)) 48* (90.6) 5* (9.4) 53* (100.0) 11 (35.5) 20 (64.5) 31 (100.0)
Previous cardiovascular discharge
diagnoses (%)
19 (39.6) 2 (40.0) 21 (39.6) 3 (27.3) 9 (45.0) 12 (38.7)
Age (years (SD)) 70.6 (3.0) 72.1 (2.4) 70.7 (2.9) 70.4 (2.9) 72.1 (3.1) 71.6 (3.1)
Pre-operative S-creatinine (mmol/l (SD)) 99.6** (25.3) – – 121.0 (39.7) – –
Aortic tube graft (%) 35 (72.9) 3 (60.0) 38 (71.7) 6 (54.5) 11 (55.0) 17 (54.8)
Operation time (min (SD)) 135** (46.1) 96.3 (62.1) 132** (47.9) 179 (91.5) 161.1 (101.2) 166 (97.3)
Wound complications (%) 6 (12.5) 1 (20.0) 7 (13.2) 1 (9.1) 2 (10.0) 3 (9.7)
Surgical complications (%) 6 (12.5) 1 (20.0) 7 (13.2) 0 (0.0) 5 (25.0) 5 (16.1)
Medical complications (%) 7 (14.6) 1 (20.0) 8 (15.1) 1 (9.1) 10 (50.0) 11 (35.5)
Total complications (%) 12 (25.0) 1 (20.0) 13 (24.5) 2 (18.2) 12 (60.0) 14 (45.2)
Transfusions (units (SD)) 0.41 (0.91) 0.20 (0.20) 0.42** (0.88) 0.89 (1.54) 2.62 (5.93) 2.11 (5.16)
Admission time (days (SD)) 10.0 (5.1) 12.8 (19.4) 10.2 (6.8) 10.0 (5.1) 9.2 (11.3) 9.5 (9.8)
*P!0.05 (Chi square test comparing the invited group with the control group). **P!0.05 (t-test comparing the invited group with the control
group).
J. S. Lindholt et al.12reported, within 5 years after randomization there
were 9 AAA deaths in the invited group compared to
27 deaths in the controls.Resources use and unit costs
Table 1 shows pre-, per- and post-operative character-
istics of operations for AAA. One AAA operation was
conducted outside Viborg county. In the group invited
to screening there were 53 AAA-related operations
(five emergency and 48 planned) compared to 31 in
controls (20 emergency and 11 planned). Thus the
frequency of acute operations was reduced by 75%
(95% CI: 34–91%) in the screening group compared
to controls (Chi square, PZ0.003). The planned
operations in the screening group were shorter, tended
to involve less blood loss and more often required an
aortic–aortic tube graft. Nevertheless, the frequency of
complications was similar in the two groups (25 versus
18%, Chi square, PZ0.931).
Table 2 shows the overall number of events
observed in each arm. The initial screening invitation
to 6333 men generated 512 follow up scans after the
initial scan. In the screening group, there were 40Table 2. The overall number of events and their cumulated costs in t
Activity Price per unit (D
Screening 83.75
Surveillance 83.75
Re-screening 83.75
AAA admissions with uncomplicated operations 79,000
AAA admissions with complicated operations 131,000
Total
Difference Danish Crowns (Dkr)
Difference Euro (V)
Difference Pounds (£)
£1Z10.86 DKr the 1st of January 2006. V1Z7.46 DKr the 1st of January
Eur J Vasc Endovasc Surg Vol 32, July 2006uncomplicated and 13 complicated operations, while
among controls, there were 17 and 14, respectively
(PZ0.051). Table 2 also summarises the unit costs
estimated for these events. The excess costs in the
screened group totalled V288,908, corresponding to
V45.62 per invited person.
Table 3 shows estimates of the number of life years
saved. The main assumptions behind the estimates
were that non-AAA mortality is unaffected by screen-
ing and that screening has a net effect on AAA-
mortality only between 1.5 and 5 years after the
screening invitation. The AAA-mortality rate differ-
ence was 0.89 per 1000 years (95% CI: 0.40–1.37), as
observed in the present study. After 5 years the AAA
mortality again was assumed to be unaffected by
screening.Cost benefit and effectiveness
In the screening group nine died from AAA compared
to 27 in the control group, corresponding to a 67%
(95% CI: 46.0–83.5%) decrease in AAA-specific mor-
tality (Fig. 2, PZ0.003). Consequently, the estimated
cost per prevented death of AAA wasV16,050 (95% CI:he screening and control group
kr) Screening group Control group
N Costs (Dkr) N Costs (Dkr)
4843 405,601.30
512 42,880.00
248 20,770.00
40 3160,000.00 17 1343,000.00
13 1703,000.00 14 1834,000.00
5332,251.30 3177,000.00
2155,251.30
V288,907.68
£198,457.76
2006.
Table 3. Estimated life-years gained and cost effectiveness by inviting 6333 persons for screening
Period after
invitation
Expected remaining years of life Difference Cost per gained living year
Invited Controls 95% CI Mean 95% CI
0–5 years 29,167.1 29,135.1 31.9 14.4–49.2 Dkr 67,563 Dkr 43,806–149,670
V9057 V5872–20,063
£6221 £4034–13,782
0–10 years 52,275.1 52,168.4 106.7 47.9–164.3 Dkr 20,199 Dkr 13,118–44,995
V2708 V1758–6031
£1860 £1208–4143
0–15 years 68,245.1 68,086.8 158.3 71.1–243.8 Dkr 13,615 Dkr 8840–30,313
V1825 V1185–4063
£1254 £814–2791
£1Z10.86 DKr the 1st of January 2006. V1Z7.46 DKr the 1st of January 2006.
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Cost-effectiveness of Screening for AAA 13V12,815–23,261). This is equivalent to £10,793 (95% CI:
£8672–15,641). The overall mortality hazard ratio was
0.33 (95% CI: 0.16–0.71; PZ0.003). However, as
mentioned, the proportional hazards assumption for
Cox regression was not met (PZ0.03). Consequently,
the follow up was split into two time periods, each
with a separate analysis. During the first 18 months
after randomisation the AAA mortality seemed
similar between the two groups (hazard rate ratio
0.77; 95% CI: 0.29–2.07; PZ0.61), but thereafter the
AAA-mortality in the intervention group was much
lower than in the control group (hazard ratio 0.11; 95%
CI: 0.03–0.48; PZ0.003).
Table 3 shows the estimated number of life years
saved after 5, 10, and 15 years, and the corresponding
costs per saved life year. We estimated that the
screening invitation to the 6333 men will save 32 life-
years (95% CI: 14–49) during the first 5 years. Thus, the
cost per year of life saved was V9057 (V5872–20,063).
This is equivalent to £6221 (4034–13,782).
If the prediction is extended to 10 and 15 years, 107
(95% CI: 48–164) and 158 (95% CI: 71–243) life-years will
be saved, respectively. The costs per saved life-year
would then be V2708 (V1758–6031) after 10 years and
V1825 (V1185–4063) after 15 years. This is equivalent to
£1860 after 10 years and £1254 after 15 years.Invited
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Fig. 2. Kaplan–Meier estimates of mortality from abdominal
aortic aneurysms. Screening group and control group.Discussion
In this cost-effectiveness analysis, screening for AAA
reduced the frequency of acute operations by 75%, and
AAA-specific mortality by 67%. The cost per AAA
death prevented was about V16,050 (£10,793), and
V9057 (£6221) per saved life-year. In our previous
report from 2002,13 the number of participants was
believed to be 12,658, but when we analysed the
newest mortality data, we realised that 19 actually had
died, but not yet removed from the population register
before the date of randomisation.Costs
The major costs were due to operative admissions. As
mentioned, specific DRG costs for admissions to AAA-
surgery were not defined in 1999; only those for
uncomplicated or complicated major heart or major
vascular surgery including AAA surgery. Conse-
quently, we did an analysis on a random sample of
100 admissions for elective and emergency AAA
performed in Viborg Hospital from 1996 to 1998.14,19
The method and results are published elsewhere, but
briefly, the patient-records were used to estimate the
costs of these admissions.20 Cost estimates for each
part of the operative admissions, e.g. working time,
salaries, utensils, were based on 1998 prices.14 Over-
head for administration, heating, electricity, rent,
discount, and depreciation of the equipment were
incorporated. Other costs, such as indirect costs,
salaries for the medical staff, and costs of transpor-
tation, were not included. Clinician and staff time in
addition to the surgery was estimated by consensus
between two representatives from each of the involved
groups of staff, while the duration of surgery wasEur J Vasc Endovasc Surg Vol 32, July 2006
J. S. Lindholt et al.14obtained from the patients’ records. Prices were given
by the hospital administrations, and mean salaries
were used.
The resulting costs were V9330 for uncomplicated
operations compared to a DRG tariff of V10,590, and
V17,292 for complicated operations compared to a
DRG tariff of V17,560. Consequently, we believe the
used DRG tariffs are representative for AAA oper-
ations. However, the costs for a planned operation
were V12,321, and for emergency operation were
V13,997, compared to V10,345 and V16,732 for
planned and emergency operations in the similar but
larger British MASS trial.11 If the operative costs from
the MASS trial are used, the costs per saved life and
costs per gained life-year would be V10,808 and
V6099, respectively. In all, the DRG tariffs used
resulted in the least attractive cost effectiveness of
screening for AAA.The benefits
Surprisingly, no deaths due to AAAwere observed after
28 months in the group randomized to screening.
Among those who attended screening, elective pro-
cedures rapidly became less common after the first 2
years. Therefore, the risk of death due to elective surgery
was small, although from the experience of the control
group four AAA-deaths were expected among those
invited to screening who did not attend. The difference,
however, was not statistically significant, and could
merely be the result of chance. Alternatively, selection
could be an explanation. We know from our earlier
studies of this population that those with AAA-
associated diseases attend screening more frequently
than those without.21,22 Therefore, the prevalence of
AAA among non-attenders could be expected to be
lower than among attenders and so there would
consequently be fewer ruptures than in the total
population. The main results presented are limited by
the relatively short observation period. This limitation is
a conservative one because benefits are expected to
increase with time without additional costs. We
extrapolated the results to 10 and 15 years of follow-
up, and the cost-effectiveness seems to become even
more attractive by a factor of at least 5 after 10 years.Comparison to the MASS trial
The results from the similar MASS-trial in the UK
provide some contrast to this study.11,23 Their cost per
life-year saved was £28,400 compared to £6221 per life-
year saved in our present study, so the cost-
effectiveness seems more attractive in our study.Eur J Vasc Endovasc Surg Vol 32, July 2006There are probably several reasons for this. First, the
benefit of screening concerning reduced mortality
tended to be higher in our study (67 versus 42%),
although it was not statistically significantly different
(Chi square, PZ0.17). Second, the total costs, fre-
quency, and mortality, of emergency AAA surgery
were higher in our study. Finally, the MASS trial’s
screening costs were substantially higher than ours,
and their sensitivity analyses reflected these costs. Our
screening costs were approximately one third of theirs.
This difference may relate to the fact that hospital
based screening for AAA is much easier and more
economically organized than screening at multiple
general practitioners. The enthusiasm of the small
mobile screening team in our study also could have
played a role in the cost-effectiveness we observed,
and the costs might be higher in a routine programme.
If our screening costs had been similar to the MASS
trial, our costs per life-year saved would be £8718 (95%
CI: 5652–19,311) during the first 5 years, and would be
expected to decrease to £2606 (95% CI: 1693–5806) after
10 years, which is still an acceptable cost effectiveness
according to British guidelines.12Conclusion
Screening for AAA reduced the frequency of emer-
gency operations by 75% and AAA-specific mortality
by 67%. However, the frequency of elective operations
with complications was not reduced by screening. In
all, the costs were about V16,050 per AAA death
prevented, and V9057 per life-year saved. The benefits
are expected to increase further with time, and the
costs per life-year saved to decrease. Consequently,
screening of 64–73 year old men for AAA in Denmark
seems cost effective.Acknowledgements
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